KY-0901

KY-0901 is a first-in-class bispecific nanobody-drug conjugate (ADC) developed by Novatim Immune Therapeutics. It utilizes a dual-payload strategy, carrying two distinct cytotoxic agents to enhance therapeutic efficacy and overcome resistance mechanisms. The drug is currently in the preclinical candidate (PCC) stage, targeting advanced solid tumors, specifically pancreatic cancer and cholangiocarcinoma. While the specific molecular targets of the bispecific nanobody component have not been publicly disclosed, the platform aims to leverage the high specificity and penetration of nanobodies for targeted delivery of potent payloads to tumor cells.